Skip to content

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)294-303
Number of pages10
JournalThe Lancet
Volume395
Issue number10220
Early online date23 Jan 2020
DOIs
DateAccepted/In press - 15 Nov 2019
DateE-pub ahead of print (current) - 23 Jan 2020

Abstract

Background:
In chronic central serous chorioretinopathy (CSCR), fluid accumulates in the sub-retinal space. It is a common visually disabling condition in individuals of working age. There is no definitive treatment. Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is effective for treating CSCR but it is not licensed for this indication. We evaluated whether eplerenone is superior to placebo for treating chronic CSCR.

Methods:
We conducted a placebo-controlled parallel-group randomised trial in 22 United Kingdom hospitals. Participants were aged ≥18 and ≤60 years with treatment naïve CSCR for ≥4 months. Randomisation stratified by best-corrected visual acuity (BCVA) and hospital was performed online, with participants randomised to receive oral eplerenone (25 mg/day for one week, increasing to 50 mg/day for up to 12 months) plus usual care or placebo plus usual care. Participants, care teams, outcome assessors, pharmacists and the trial management group were masked. The primary outcome was BCVA at 12 months. All outcomes apart from safety were analysed on a modified intention-to-treat basis. The trial is registered: ISRCTN92746680.

Findings:
Between 11/01/2017 and 22/02/2018, 57 participants were randomised to eplerenone and 57 to placebo; 57 and 54 participants respectively were included in the final analysis. Modelled mean BCVA at 12 months in the placebo and eplerenone groups were 79.5 (SD 4.5) and 80.4 (SD 4.6) letters, with an adjusted estimated difference (eplerenone minus placebo) of 1.73 letters (95% confidence interval -1.12 to 4.57, p=0·24) at 12 months. Hyperkalaemia occurred in eight participants in each group (14%). No serious adverse events occurred in the eplerenone group; three unrelated serious adverse events occurred in the placebo group.

Interpretation:
Eplerenone was not superior to placebo in improving BCVA in people with chronic CSCR during 12 months follow-up.

Funding
Efficacy and Mechanism Evaluation Programme, National Institute for Health Research and Social Care.

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S0140-6736(19)32981-2 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 386 KB, PDF document

    Embargo ends: 23/07/20

    Request copy

    Licence: CC BY-NC-ND

  • Supplementary information PDF

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S0140-6736(19)32981-2 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 1.75 MB, PDF document

    Embargo ends: 23/07/20

    Request copy

    Licence: CC BY-NC-ND

DOI

View research connections

Related faculties, schools or groups